Fate Therapeutics Inc (FATE)

[jondoeuk]

(OT) Indapta Therapeutics announces FDA clearance of an IND for IDP-023, an off-the-shelf NK cell therapy. The trial will explore three different dose levels of G-NK cells alone and in combination with IL-2, with rituximab or daratumumab in patients with relapsed/refractory lymphoma or multiple myeloma. G-NK cells are a specific subset of NKs https://ashpublications.org/bloodadvances/article/5/15/3021/476502/Fc-RI-negative-NK-cells-persist-in-vivo-and